<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34284776</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.</ArticleTitle><Pagination><StartPage>181</StartPage><MedlinePgn>181</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">181</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12955-021-01822-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The study aimed to appraise the health-related quality of life (HRQoL) measured by the five-level EuroQol-5 dimensions (EQ-5D-5L) in amyotrophic lateral sclerosis (ALS), and to explore the associations between non-motor symptoms (mood changes, cognitive disturbances and sleep disturbances).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">EQ-5D-5L descriptive scores were converted into a single aggregated "health utility" score. A calibrated visual analog scale (EQ-VAS) was used for self-rating of current health status. Multiple logistic regression analysis was used to explore the factors associated with HRQoL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 547 enrolled ALS patients who were assessed using EQ-5D-5L, the highest frequency of reported problems was with usual activities (76.7%), followed by self-care (68.8%) and anxiety/depression (62.0%). The median health utility score was 0.78 and the median EQ-VAS score was 70. Clinical factors corresponding to differences in the EQ-5D-5L health utility score included age of onset, onset region, the ALS Functional Rating Scale-Revised (ALSFRS-R) score, and King's College stages. Patients with depression, anxiety, and poor sleep had lower health utility scores. Patients with excessive daytime sleepiness and rapid eye movement sleep behavior disorder had lower EQ-VAS scores. Multivariate logistic analysis indicated that ALSFRS-R scores, depression, and anxiety were associated with health utility scores. After adjusting other parameters, ALSFRS-R score, stages, and depression were significantly associated with EQ-VAS scores (P&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study examined HRQoL in ALS patients using the Chinese version of the EQ-5D-5L scale across different stages of the disease. We found that HRQoL is related to disease severity and to mood disturbances. Management of non-motor symptoms may help improve HRQoL in ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Qian-Qian</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yanbing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yongping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Ruwei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tianmi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0947-1151</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China. hfshang2002@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020YFS0220</GrantID><Agency>sichuan science and technology program</Agency><Country/></Grant><Grant><GrantID>81871000</GrantID><Agency>National Science Fund of China</Agency><Country/></Grant><Grant><GrantID>2019M653427</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant><Grant><GrantID>2019HXBH029</GrantID><Agency>Post-Doctor Research Project, West China Hospital, Sichuan University</Agency><Country/></Grant><Grant><GrantID>20PJ038</GrantID><Agency>Health Commission of Sichuan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064232" MajorTopicYN="N">Visual Analog Scale</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical stage</Keyword><Keyword MajorTopicYN="N">EQ-5D-5L</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Non-motor symptoms</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.
</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34284776</ArticleId><ArticleId IdType="pmc">PMC8290546</ArticleId><ArticleId IdType="doi">10.1186/s12955-021-01822-9</ArticleId><ArticleId IdType="pii">10.1186/s12955-021-01822-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:1602. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment. Neurology. 2019;93:66&#x2013;71. doi: 10.1212/WNL.0000000000007695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007695</ArticleId><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Vinceti M, Malagoli C, Fini N, Gessani A, Fasano A, Rizzi R, Sette E, Cavazza S, Fiocchi A, et al. High-frequency motor rehabilitation in amyotrophic lateral sclerosis: a randomized clinical trial. Ann Clin Transl Neurol. 2019;6:893&#x2013;901. doi: 10.1002/acn3.765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.765</ArticleId><ArticleId IdType="pmc">PMC6529833</ArticleId><ArticleId IdType="pubmed">31139687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Campo Y, Homedes C, Lazaro A, Alarc&#xf3;n R, Campo D, Riera M, Dom&#xed;nguez R, Povedano M, Casasnovas C. Observational study of patients in Spain with amyotrophic lateral sclerosis: correlations between clinical status, quality of life, and dignity. BMC Palliat Care. 2017;16:75. doi: 10.1186/s12904-017-0260-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-017-0260-6</ArticleId><ArticleId IdType="pmc">PMC5735656</ArticleId><ArticleId IdType="pubmed">29258495</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics. 2015;12:394&#x2013;402. doi: 10.1007/s13311-014-0322-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0322-x</ArticleId><ArticleId IdType="pmc">PMC4404446</ArticleId><ArticleId IdType="pubmed">25502407</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20:662&#x2013;669. doi: 10.1016/j.jval.2016.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.11.016</ArticleId><ArticleId IdType="pubmed">28408009</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schroder R, Heuss D, Vielhaber S, Tackenberg B, Mylius V, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:1473&#x2013;1481. doi: 10.1007/s00415-010-5549-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5549-9</ArticleId><ArticleId IdType="pubmed">20383521</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A, Young CA, Hughes DA. Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor neuron disease. Value Health. 2018;21:1322&#x2013;1329. doi: 10.1016/j.jval.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2018.05.005</ArticleId><ArticleId IdType="pubmed">30442280</ArticleId></ArticleIdList></Reference><Reference><Citation>Peseschkian T, Cordts I, G&#xfc;nther R, Stolte B, Zeller D, Schr&#xf6;ter C, Weyen U, Regensburger M, Wolf J, Schneider I, et al. A nation-wide, multi-center study on the quality of life of ALS patients in Germany. Brain Sci. 2021;11:372. doi: 10.3390/brainsci11030372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030372</ArticleId><ArticleId IdType="pmc">PMC7998410</ArticleId><ArticleId IdType="pubmed">33799476</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Health status perspectives in amyotrophic lateral sclerosis. Neurodegener Dis. 2017;17:323&#x2013;329. doi: 10.1159/000480638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480638</ArticleId><ArticleId IdType="pubmed">29084402</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, Young C, Shaw PJ, Leigh PN, Turner MR, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:285&#x2013;291. doi: 10.3109/21678421.2013.872149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.872149</ArticleId><ArticleId IdType="pubmed">24641613</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groenestijn AC, Kruitwagen-van Reenen ET, Visser-Meily JM, van den Berg LH, Schroder CD. Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review. Health Qual Life Outcomes. 2016;14:107. doi: 10.1186/s12955-016-0507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-016-0507-6</ArticleId><ArticleId IdType="pmc">PMC4955215</ArticleId><ArticleId IdType="pubmed">27439463</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135:2883&#x2013;2891. doi: 10.1093/brain/aws144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws144</ArticleId><ArticleId IdType="pubmed">22661746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, Guo X, Huang R, Cao B, Zeng Y, Shang H. The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:237&#x2013;244. doi: 10.3109/21678421.2014.993650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.993650</ArticleId><ArticleId IdType="pubmed">25581512</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wei QQ, Chen Y, Cao B, Ou R, Hou Y, Yuan X, Zhang L, Liu H, Shang H. Clinical staging of amyotrophic lateral sclerosis in Chinese patients. Front Neurol. 2018;9:442. doi: 10.3389/fneur.2018.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00442</ArticleId><ArticleId IdType="pmc">PMC6018204</ArticleId><ArticleId IdType="pubmed">29971035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55:1621&#x2013;1626. doi: 10.1212/WNL.55.11.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.11.1621</ArticleId><ArticleId IdType="pubmed">11113214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, Huang R, Guo X, Cao B, Bak TH, Shang H. Screening for cognitive impairment in a Chinese ALS population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:40&#x2013;45. doi: 10.3109/21678421.2014.966311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.966311</ArticleId><ArticleId IdType="pubmed">25309978</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Zhao X, Liu Q, Liu S, Zhang K, Wang ZL, Yang X, Shang L, Huang Y, Cui L, Zhang X. Study on sleep-wake disorders in patients with genetic and non-genetic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiebert GM, Green C, Murphy C, Mitchell JD, O'Brien M, Burrell A, Leigh PN. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:87&#x2013;93. doi: 10.1016/S0022-510X(01)00616-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00616-5</ArticleId><ArticleId IdType="pubmed">11676997</ArticleId></ArticleIdList></Reference><Reference><Citation>Green C, Kiebert G, Murphy C, Mitchell JD, O'Brien M, Burrell A, Leigh PN. Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis. Qual Life Res. 2003;12:565&#x2013;574. doi: 10.1023/A:1025052609818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1025052609818</ArticleId><ArticleId IdType="pubmed">13677501</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve. 2012;46:9&#x2013;25. doi: 10.1002/mus.23245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23245</ArticleId><ArticleId IdType="pubmed">22644588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazenberg A, Kerstjens HA, Prins SC, Vermeulen KM, Wijkstra PJ. Is chronic ventilatory support really effective in patients with amyotrophic lateral sclerosis? J Neurol. 2016;263:2456&#x2013;2461. doi: 10.1007/s00415-016-8288-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8288-8</ArticleId><ArticleId IdType="pmc">PMC5110605</ArticleId><ArticleId IdType="pubmed">27638636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Busschbach J, Liu G, Luo N. EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes. 2018;16:210. doi: 10.1186/s12955-018-1036-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-018-1036-2</ArticleId><ArticleId IdType="pmc">PMC6225616</ArticleId><ArticleId IdType="pubmed">30409137</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Gaur N, Stubendorff B, R&#xf6;diger A, Witte OW, Grosskreutz J. Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. J Neurol Sci. 2019;397:92&#x2013;95. doi: 10.1016/j.jns.2018.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.12.035</ArticleId><ArticleId IdType="pubmed">30597420</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Witte OW, Gunkel A, Grosskreutz J. Cognitive deficits have only limited influence on health-related quality of life in amyotrophic lateral sclerosis. Aging Ment Health. 2020;24:1963&#x2013;1967. doi: 10.1080/13607863.2019.1642296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607863.2019.1642296</ArticleId><ArticleId IdType="pubmed">31317778</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nat Sci Sleep. 2019;11:97&#x2013;111. doi: 10.2147/NSS.S183504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSS.S183504</ArticleId><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RL, Phillips LH. The psychological, neurochemical and functional neuroanatomical mediators of the effects of positive and negative mood on executive functions. Neuropsychologia. 2007;45:617&#x2013;629. doi: 10.1016/j.neuropsychologia.2006.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2006.06.030</ArticleId><ArticleId IdType="pubmed">16962146</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>